Monte Rosa Therapeutics, Inc. - Common Stock (GLUE)
12.31
-0.70 (-5.38%)
NASDAQ · Last Trade: Nov 9th, 2:14 AM EST
Detailed Quote
Previous Close
13.01
Open
12.73
Bid
12.25
Ask
12.70
Day's Range
11.90 - 13.37
52 Week Range
3.500 - 13.59
Volume
730,414
Market Cap
607.91M
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,288,609
Chart
About Monte Rosa Therapeutics, Inc. - Common Stock (GLUE)
Monte Rosa Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address challenging diseases, particularly in the field of oncology. The company utilizes its proprietary technology platform to design and optimize drug candidates that target specific protein degradation pathways, allowing for a more precise and effective approach to treatment. Monte Rosa's research aims to unlock new potential in therapeutic applications by leveraging advancements in targeted protein modulation, ultimately improving outcomes for patients suffering from various types of cancer and other serious illnesses. Read More
Data support NEK7 as a potential novel and differentiated therapeutic approach to modulate the NLRP3 inflammasome in multiple cardiovascular and cardiometabolic diseases, including pericarditis and atherosclerosis
Monte Rosa Therapeutics (GLUE) Q3 2025 earnings crushed estimates, with revenue of $12.8M. The stock is up on strong results and a cash runway extending into 2028.
Second agreement signed with Novartis to develop novel degraders for immune-mediated diseases, providing upfront payment of $120 million plus option maintenance payments, and eligibility for option exercise payments, milestones, and tiered royalties
BOSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in fireside chats at the following investor conferences:
MRT-6160 inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly, in a spontaneous autoimmune disease mouse model
Looking for insights into the US markets in the middle of the day on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
Monte Rosa Therapeutics (GLUE) reported Q2 2025 earnings with revenue beating estimates at $23.2M and a narrower EPS loss of -$0.15. Shares dipped pre-market despite strong results, as investors await clinical progress in its molecular glue degrader pipeline.
Phase 1 study of NEK7-directed molecular glue degrader (MGD) MRT-8102 underway, to investigate a potential novel therapeutic approach for treating inflammatory diseases driven by the NLRP3 inflammasome; initial readout anticipated in H1 2026
MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial results anticipated in H1 2026
Monte Rosa’s AI/ML-powered insights dramatically increase targetable protein space for molecular glue degraders, unlocking new opportunities to address previously undruggable therapeutic targets
MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio
BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 12:50 p.m. EDT.
